Improving Fmoc Solid Phase Synthesis of Human Beta Defensin 3.
cys residue protecting groups
disulfide bond
fmoc solid phase synthesis
human beta defensin 3
pseudoproline dipeptides
selenocysteine
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
19 Oct 2022
19 Oct 2022
Historique:
received:
02
09
2022
revised:
12
10
2022
accepted:
14
10
2022
entrez:
27
10
2022
pubmed:
28
10
2022
medline:
29
10
2022
Statut:
epublish
Résumé
Human β-defensin 3, HBD-3, is a 45-residue antimicrobial and immunomodulatory peptide that plays multiple roles in the host defense system. In addition to interacting with cell membranes, HBD-3 is also a ligand for melanocortin receptors, cytokine receptors and voltage-gated potassium channels. Structural and functional studies of HBD-3 have been hampered by inefficient synthetic and recombinant expression methods. Herein, we report an optimized Fmoc solid-phase synthesis of this peptide using an orthogonal disulfide bonds formation strategy. Our results suggest that utilization of an optimized resin, coupling reagents and pseudoproline dipeptide building blocks decrease chain aggregation and largely improve the amount of the target peptide in the final crude material, making the synthesis more efficient. We also present an alternative synthesis of HBD-3 in which a replacement of a native disulfide bridge with a diselenide bond improved the oxidative folding. Our work enables further biological and pharmacological characterization of HBD-3, hence advancing our understanding of its therapeutic potential.
Identifiants
pubmed: 36293413
pii: ijms232012562
doi: 10.3390/ijms232012562
pmc: PMC9603898
pii:
doi:
Substances chimiques
beta-Defensins
0
Ligands
0
Disulfides
0
Peptides
0
Dipeptides
0
Potassium Channels, Voltage-Gated
0
Receptors, Cytokine
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : National Science Center
ID : 2014/15/D/ST5/03941
Références
J Immunol. 2006 Jul 15;177(2):782-6
pubmed: 16818731
Antimicrob Agents Chemother. 2006 Feb;50(2):806-9
pubmed: 16436752
ACS Chem Biol. 2010 Jan 15;5(1):47-62
pubmed: 19957967
Front Microbiol. 2021 Feb 22;12:616979
pubmed: 33692766
Angew Chem Int Ed Engl. 2020 Jul 6;59(28):11218-11232
pubmed: 31867866
Infect Immun. 2014 Nov;82(11):4458-65
pubmed: 25114113
Immunol Res. 2014 Jan;58(1):139-53
pubmed: 23666811
FEBS J. 2013 Jul;280(14):3365-75
pubmed: 23659571
Nat Rev Drug Discov. 2020 May;19(5):311-332
pubmed: 32107480
Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8880-5
pubmed: 12840147
Pept Res. 1995 Nov-Dec;8(6):321-7
pubmed: 8838415
Biopolymers. 2010;94(2):257-64
pubmed: 20225300
J Invest Dermatol. 2013 Feb;133(2):460-8
pubmed: 22951718
Chembiochem. 2013 Jan 2;14(1):137-46
pubmed: 23229141
Org Lett. 2011 Feb 18;13(4):568-71
pubmed: 21235223
Biochemistry. 1999 Aug 10;38(32):10606-14
pubmed: 10441158
J Am Chem Soc. 2010 Mar 17;132(10):3514-22
pubmed: 20163143
Angew Chem Int Ed Engl. 2011 May 2;50(19):4423-7
pubmed: 21504031
PLoS One. 2015 Feb 23;10(2):e0117913
pubmed: 25706284
Biochemistry. 2010 Mar 30;49(12):2741-52
pubmed: 20175537
J Immunol. 2006 Dec 15;177(12):8658-66
pubmed: 17142766
J Biol Chem. 2006 May 19;281(20):14136-43
pubmed: 16500898
Peptides. 2018 Oct;108:14-18
pubmed: 30121363
Chem Soc Rev. 2021 Oct 4;50(19):11098-11155
pubmed: 34605832
Front Oncol. 2019 May 03;9:341
pubmed: 31131258
Front Immunol. 2021 Sep 14;12:712781
pubmed: 34594328
Nat Commun. 2021 Feb 8;12(1):870
pubmed: 33558523
J Mol Biol. 1998 Dec 4;284(3):779-92
pubmed: 9826515
Angew Chem Int Ed Engl. 2009;48(12):2221-4
pubmed: 19206132
Curr Top Med Chem. 2017;17(5):620-628
pubmed: 27411322
J Am Chem Soc. 2002 May 29;124(21):6063-76
pubmed: 12022841
BMC Bioinformatics. 2007 Feb 27;8:65
pubmed: 17324296
J Am Chem Soc. 2009 Nov 25;131(46):16927-31
pubmed: 19863095
PLoS One. 2015 Jun 03;10(6):e0126868
pubmed: 26038828
Nat Immunol. 2005 Oct;6(10):995-1001
pubmed: 16155572
Infect Immun. 2009 Nov;77(11):5035-43
pubmed: 19737896
Biopolymers. 1996 Jun;38(6):733-44
pubmed: 8652794
Chem Biol. 2013 Jun 20;20(6):784-95
pubmed: 23790489
Protein Sci. 1999 Aug;8(8):1605-13
pubmed: 10452604
Oncotarget. 2016 Nov 15;7(46):75902-75913
pubmed: 27713149
J Pept Sci. 2011 Jan;17(1):1-7
pubmed: 20814907
Chem Sci. 2016 Apr 21;7(4):2666-2673
pubmed: 28660039
J Pept Sci. 2007 Feb;13(2):81-93
pubmed: 17031870
J Biol Chem. 2002 Mar 8;277(10):8279-89
pubmed: 11741980
Science. 1994 Nov 4;266(5186):776-9
pubmed: 7973629
J Biol Chem. 2001 Feb 23;276(8):5707-13
pubmed: 11085990
Org Lett. 2013 Feb 1;15(3):616-9
pubmed: 23320397
Annu Rev Biophys Biomol Struct. 1997;26:357-71
pubmed: 9241423
Biochemistry. 2005 Jul 19;44(28):9804-16
pubmed: 16008365
Mini Rev Med Chem. 2006 Oct;6(10):1063-73
pubmed: 17073706
J Chem Inf Model. 2021 Sep 27;61(9):4670-4686
pubmed: 34473496
Chem Asian J. 2009 May 4;4(5):630-40
pubmed: 19235822